ACP
STRO icon

Acuta Capital Partners’s Sutro Biopharma STRO Stock Holding History

Acuta Capital Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.97M Buy
270,251
+826
+0.3% +$25.8K 6.25% 4
2026
Q1 		$6.71M Buy
269,425
+201,974
+299% +$3.65M 4.73% 6
2025
Q4 		$780K Buy
+67,451
New +$640K 0.53% 24
2019
Q2 		– Sell
-4,550
Closed -$518K – 38
2019
Q1 		$518K Hold
4,550
– – 0.25% 30
2018
Q4 		$410K Buy
+4,550
New +$549K 0.31% 19

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Acuta Capital Partners's STRO Position: Q2 2026 in Review

Acuta Capital Partners increased its Sutro Biopharma (STRO) stake by 0.31% in Q2 2026, buying an estimated $25.8K and bringing the position to 270,251 shares worth $8.97M. The position accounts for 6.25% of the portfolio, ranked #4.

Acuta Capital Partners first reported a position in STRO in Q4 2018 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Acuta Capital Partners held 270,251 shares of Sutro Biopharma worth $8.97M as of Q2 2026.
  • Acuta Capital Partners bought 826 Sutro Biopharma shares in Q2 2026, an estimated $25.8K.
  • Sutro Biopharma made up 6.25% of Acuta Capital Partners's portfolio in Q2 2026, its #4 holding.
  • Acuta Capital Partners first reported a position in Sutro Biopharma in Q4 2018 and has held it in 5 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.